Table 1 Characteristics
Characteristics | N (%) | |
|---|---|---|
Median age at diagnosis: years (min–max) | 60.7 (47–78) | |
Lymph node status | Positive | 32 (76%) |
Negative | 10 (24%) | |
Her2 status | Positive | 3 (7%) |
Negative | 25 (60%) | |
Unknown | 14 (33%) | |
HR status | Positive | 42 (100%) |
Neoadjuvant chemotherapy | Yes | 4 (9.5%) |
No | 38 (90.5%) | |
Adjuvant chemotherapy | Yes | 33(78.6%) |
No | 9(21.4%) | |
Adjuvant AI treatment | Yes | 42(100%) |
Tamoxifen before AI during adjuvant treatment | Yes | 9 (21.4%) |
No | 33 (78.6%) | |
Median duration of AI adjuvant treatment: months (min–max) | 60.0 (41-85) | |
Median delay between end of adjuvant treatment and relapse: months (min–max) | 25 (2–71) | |
Type of relapse | Local | 1 (2.4%) |
Metastatic | 41 (97.6%) | |
Median duration of follow-up during metastatic setting: months (min–max) | 32.9 (1–75) | |